N@N

Data on ARIAD's Oncology Pipeline to Be Presented at the 2010 ASCO Annual Meeting

^{Published on 2010-05-21 04:45:34 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that new data on [ AP24534 ], its investigational pan-BCR-ABL inhibitor, and [ ridaforolimus ], its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois being held June 4 to 8, 2010.

The schedule and meeting location for the sessions, together with the abstract information, are listed below by program:

AP24534

Title: Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and other hematologic malignancies
Date & Time: Monday, June 7, 2010, 2:00 PM a" 6:00 PM (with presentation at 5:00 PM)
Abstract: #53232
Presenter: Moshe Talpaz, M.D. (University of Michigan)
Location: Exhibit Hall, 354a

Ridaforolimus

Title: A phase 1 study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors
Date & Time: Saturday, June 5, 2010, 1:30 PM - 2:00 PM
Abstract: #48347
Presenter: Serena Di Cosimo, M.D. (Breast Cancer Center, Vall d'Hebron University Hospital)
Location: Exhibit Hall, D2

Title: A multi-center, first-in-pediatrics phase 1 study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors
Date & Time: Sunday, June 6, 2010, 5:00 PM a" 6:00 PM
Abstract: #48828
Presenter: Lia Gore, M.D. (University of Colorado Denver and The Children's Hospital)
Location: Room S 504

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].